


In the claims:

Please cancel claims 1-68.

Claims 1-68 (Canceled).

Please add the following new claims.


69. (New) An isolated agent comprising the core structure TPI 927 having the formula:



wherein said agent derepresses an inhibitor of apoptosis protein- (IAP-) inhibited caspase.






70. (New) The isolated agent of claim 69, wherein the R group of said agent is selected from the group consisting of:

an R1 group selected from:









;











an R2 group selected from:











;

an R3 group selected from:








71. (New) The isolated agent of claim 69, wherein said agent is selected from the group consisting of a compound as shown in Figure 22A.

72. (New) The agent of any of claims 69 to 71, wherein said agent derepresses an X chromosome linked IAP- (XIAP-) inhibited caspase.

73. (New) The agent of any of claims 69 to 71, wherein said agent derepresses an XIAP-inhibited caspase-3.







74. (New) A pharmaceutical composition comprising the agent of claims 69 to 71 and a pharmaceutically acceptable carrier.

75. (New) A complex comprising an IAP bound to an agent comprising the core structure TPI 927 having the formula








76. (New) The complex of claim 75, wherein the R group of said agent is selected from the group consisting of:

an R1 group selected from:








;










an R2 group selected from:




;

an R3 group selected from:









77. (New) The complex of claim 75, wherein said agent is selected from the group consisting of a compound as shown in Figure 22A.

78. (New) The complex of any of claims 75 to 77, wherein said IAP is selected from the group consisting of XIAP, c-IAP-1, c-IAP-2, and survivin.

79. (New) The complex of claim 78, wherein said IAP is XIAP.

80. (New) The complex of claim 78, wherein said IAP is c-IAP-1.

81. (New) The complex of claim 78, wherein said IAP is c-IAP-2.

82. (New) The complex of claim 78, wherein said IAP is survivin.

83. (New) A method of derepressing an IAP-inhibited caspase, comprising contacting an IAP-inhibited caspase with an effective amount of the agent of any of claims 69-71 to derepress an IAP-inhibited caspase.

84. (New) The method of claim 83, wherein said IAP is selected from the group consisting of XIAP, c-IAP-1, c-IAP-2, and survivin.

85. (New) The method of claim 83, wherein said caspase is selected from the group consisting of caspase-3, caspase-7 and caspase-9.

86. (New) The method of claim 83, wherein said contacting is performed *in vitro*.

87. (New) The method of claim 83, wherein said contacting occurs in a cell.